On May 25-27, COVend participated in the Euroanaesthesia 2024 Congress in Munich, Germany, organised by our partner, the European Society of Anaesthesiology and Intensive Care (ESAIC). This was a significant moment for our project as we had the opportunity to showcase our progress and achievements in the fight against COVID-19 to a global audience of over 6,000 onsite and 700 virtual attendees from more than 110 countries. 

The Euroanaesthesia Congress is a highly influential event in the fields of anaesthesiology, intensive care, emergency medicine, and pain management. This year’s theme, “The Power of Connection: Transforming Healthcare Together,” highlighted the importance of collaboration in modern medicine. The congress brought together experts, researchers, and clinicians to exchange knowledge and present advancements in the field. 

The COVend project was prominently featured at the EU booth, part of the main ESAIC stand, which was a highlight of the congress. The posters displayed at the booth provided detailed information about COVend’s novel effective FX06 therapy against endothelial damage in ARDS for the clinical management of COVID-19 and other diseases. In addition, these posters offered an in-depth look at the unique IXION 2.0 clinical trial. 

During the ESAIC Expo on May 27, COVend project coordinator Prof. Dr. Dr. Kai Zacharowski presented the potential of FX06 to improve disease severity in ARDS patients. We were honored to have the opportunity to showcase COVend at such a prestigious event, as the congress not only serves as a meeting point for professionals but also as a starting ground for healthcare innovations. We look forward to more opportunities like this in the future. 

 

For more information about ESAIC and the COVend IXION 2.0 clinical trial, please follow the links. The posters from the congress are available here.